Glenmark Pharmaceuticals wins the ‘India Pharma Innovation of the Year’ Award
The prestigious “India Pharma Innovation of the Year” award, as part of the India Pharma and India Medical Device Awards 2021, has been conferred on Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company.
The India Pharma Innovation of the Year award has been presented by the Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers to Glenmark Pharmaceuticals as a recognition of Glenmark’s multiple patents and commercialised innovations over the last three years. This is the fourth time Glenmark has won an award from the Government of India.
The award recognises the company’s multiple achievements in the areas of dermatology, respiratory and oncology, over the last three years. It also acknowledges the company’s contribution to the healthcare sector in terms of providing for both pressing and long-term patient needs. Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals, said, “Now more than ever, needs continuous innovation to address infectious and chronic diseases. Our goal at all times is to be future-ready, and to this end, innovation is ingrained in all our efforts. We thank the government for its recognition; it serves as an encouraging reminder to keep up our good work in India and the world.” Glenmark has previously won awards from the Department of Pharmaceuticals under the categories of India Pharma Leader Award (2015), Company of the Year (2016), and Corporate Social Responsibility Program of the Year (2017).
Glenmark Pharmaceuticals (GPL) is a global research-led pharma company with presence across Generics, Specialty, and OTC business. It operates across over 50 countries. Globally, Glenmark’s main therapy focus areas are respiratory, dermatology and oncology. It is ranked amongst the top 80 pharma and biotech companies worldwide in terms of revenue. It has also been listed in the Dow Jones Sustainability Index (DJSI) under the category of emerging markets for the third year in a row.